Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026

Biodexa Pharmaceuticals filed Prospectus Supplement No. 3 to its F-1 resale prospectus, registering up to 127,754,750 ordinary shares (2,555,095 ADSs) issuable upon exercise of pre-funded, Series M, Series N, and Series O warrants sold in July 2026 offerings and a warrant inducement transaction. The supplement incorporates a 6-K announcing that the ADS ratio will change from 1 ADS per 50 ordinary shares to 1 ADS per 400 ordinary shares, effective on or about October 26, 2026 — effectively a mandatory one-for-eight reverse ADS split requiring holders to exchange old ADSs (CUSIP 59564R872) for new ADSs (CUSIP 59564R864).

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.